Cedar Point Capital Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
Cedar Point Capital Partners's LLY Position: Q2 2026 in Review
Cedar Point Capital Partners increased its Eli Lilly (LLY) stake by 23% in Q2 2026, buying an estimated $63.3K and bringing the position to 337 shares worth $404K. The position accounts for 0.23% of the portfolio, ranked #53.
Cedar Point Capital Partners first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,634 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Cedar Point Capital Partners held 337 shares of Eli Lilly worth $404K as of Q2 2026.
- Cedar Point Capital Partners bought 62 Eli Lilly shares in Q2 2026, an estimated $63.3K.
- Eli Lilly made up 0.23% of Cedar Point Capital Partners's portfolio in Q2 2026, its #53 holding.
- Cedar Point Capital Partners first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
- 4,634 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Cedar Point Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.